Aclaris Therapeutics (ACRS) Research Coverage Started at Guggenheim

Equities research analysts at Guggenheim started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set a “buy” rating on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Monday, January 8th. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Aclaris Therapeutics currently has an average rating of “Hold” and an average target price of $39.20.

Shares of Aclaris Therapeutics (ACRS) traded down $0.33 during mid-day trading on Thursday, reaching $19.57. 466,281 shares of the company’s stock traded hands, compared to its average volume of 379,381. Aclaris Therapeutics has a 12-month low of $18.52 and a 12-month high of $33.25. The firm has a market cap of $598.19, a price-to-earnings ratio of -9.06 and a beta of 1.26.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. equities research analysts predict that Aclaris Therapeutics will post -2.59 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. grew its position in shares of Aclaris Therapeutics by 40.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after acquiring an additional 17,804 shares during the period. Cadence Capital Management LLC bought a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at about $689,000. Boothbay Fund Management LLC grew its position in shares of Aclaris Therapeutics by 60.3% in the 3rd quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock valued at $535,000 after acquiring an additional 7,791 shares during the period. Citadel Advisors LLC grew its position in shares of Aclaris Therapeutics by 620.6% in the 3rd quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock valued at $6,247,000 after acquiring an additional 208,429 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Aclaris Therapeutics by 60.8% in the 2nd quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock valued at $968,000 after acquiring an additional 13,500 shares during the period. Hedge funds and other institutional investors own 92.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/08/aclaris-therapeutics-acrs-research-coverage-started-at-guggenheim.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

The Fly

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply